English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2020 → 2021: -47.07%
Price change 2021 → 2022: 1.23%
Price change 2022 → 2023: -8.78%
Price change 2023 → 2024: -72.51%
Price change 2024 → 2025: 34.65%
Price change 2025 → 2026: 50.50%
Price change 2026 (year to date): 54.20%
Financial growth
Revenue CAGR (8 years): 29.26%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.04
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -4.41
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 32.65% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="FDMT" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. | – | 0.04 | +40.0 % | 🔒 |
| Lumibird S.A. | 38.8 | 0.71 | +9.8 % | – |
| Valneva SE | – | 1.95 | +22.4 % | – |
| Pharming Group N.V. | 38.2 | 0.42 | +50.1 % | – |
| DocMorris AG | – | 0.71 | +5.7 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by 4D Molecular Therapeutics, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 13.6 m | -56.7 m | -416.5 % | n/a |
| 2021 | 18.0 m | -71.3 m | -395.4 % | +32.5 % |
| 2022 | 3.1 m | -107 m | -3,435.4 % | -82.7 % |
| 2023 | 20.7 m | -101 m | -486.6 % | +562.3 % |
| 2024 | 37,000 | -161 m | -434,778.4 % | -99.8 % |
| 2025 | 85.2 m | -140 m | -164.4 % | +230,194.6 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by 4D Molecular Therapeutics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 248 m | 214 m | 288 m | 425 m | 403 m |
| Total Debt | 16.4 m | 16.1 m | 14.7 m | 24.6 m | 21.4 m |
| Net Debt | -137 m | -36.2 m | -234 m | -125 m | -38.8 m |
| Equity | 319 m | 231 m | 308 m | 511 m | 506 m |
| Total assets | 353 m | 262 m | 340 m | 560 m | 567 m |
| Operating cash flow | -69.1 m | -86.7 m | -75.8 m | -135 m | -109 m |
| Investments (capex) | 9.1 m | 11.5 m | 2.8 m | 3.8 m | 536,000 |
| Free cash-flow | -78.2 m | -98.2 m | -78.6 m | -138 m | -109 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
4D Molecular Therapeutics, Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc. | 657 m | n/a | -164.4 % |
| REGENXBIO Inc. RGNX | 475 m | n/a | -113.8 % |
| Ocugen, Inc. OCGN | 238 m | n/a | -1,537.4 % |
| Abeona Therapeutics Inc. ABEO | 249 m | n/a | 1,223.1 % |
| MeiraGTx Holdings plc MGTX | 911 m | n/a | -140.3 % |
| Lexeo Therapeutics, Inc. Common Stock LXEO | 258 m | n/a | 0.0 % |
| uniQure N.V. QURE | 1.7 bn | n/a | -1,236.0 % |
| Solid Biosciences Inc. SLDB | 665 m | n/a | 0.0 % |
| Sector median (Nasdaq) | 20.5 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on . Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering 4D Molecular Therapeutics, Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Average target over the last 3 months: 29.67 USD (3 targets).
Track record against expectations: reported EPS above consensus 5 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
4D Molecular Therapeutics, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
Next release: 10/11/2026. Expected EPS: -1.04.
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in 4D Molecular Therapeutics, Inc.
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| State Street | 5.8 m | 77.4 m | 0.0 % | +115.0 % | 2026Q2 |
| BlackRock | 4.5 m | 60.5 m | 0.0 % | +9.7 % | 2026Q2 |
| Goldman Sachs | 4.3 m | 56.6 m | 0.0 % | +1.3 % | 2026Q2 |
| Adage Capital Partners | 2.2 m | 29.9 m | 0.0 % | +40.1 % | 2026Q2 |
| Vanguard Group | 3.1 m | 23.2 m | 0.0 % | +20.1 % | 2025Q4 |
| Citadel Advisors | 1.4 m | 18.3 m | 0.0 % | +420.7 % | 2026Q2 |
| Geode Capital Management | 1.1 m | 15.0 m | 0.0 % | +5.9 % | 2026Q2 |
| Bank of America | 1.1 m | 14.9 m | 0.0 % | +15.0 % | 2026Q2 |
Latest insider transactions
| Date | Person | Side | Amount |
|---|---|---|---|
| 16/10/2026 | Bizily Scott | sale | 20,993 USD |
| 05/10/2026 | Kirn David | sale | 750,235 USD |
| 05/10/2026 | Kirn David | sale | 3,702 USD |
| 16/09/2026 | Bizily Scott | sale | 22,318 USD |
| 14/09/2026 | Kirn David | sale | 811,004 USD |
| 01/09/2026 | Bizily Scott | sale | 8,176 USD |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 08/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about 4D Molecular Therapeutics, Inc.
What is the 4D Molecular Therapeutics, Inc. share price?
Latest recorded price: 12.25 USD on 06/11/2026, for a market cap of 677 m USD.
What is the revenue of 4D Molecular Therapeutics, Inc.?
85.2 m USD for fiscal year 2025, with net income of -140 m USD (net margin -164.4 %).
When does 4D Molecular Therapeutics, Inc. report its next earnings?
The next release is expected on 10/11/2026. EPS expected by analysts: -1.04.
What do analysts say about 4D Molecular Therapeutics, Inc.?
Out of 14 analysts: 11 buy or strong buy, 2 hold, 1 sell or strong sell. Average price target: 29.67 USD, i.e. +149.3 % from the share price.
Is 4D Molecular Therapeutics, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US35104E1001).
How many employees does 4D Molecular Therapeutics, Inc. have?
227 full-time employees according to the latest published profile.
Who runs 4D Molecular Therapeutics, Inc.?
David H. Kirn is the company's chief executive.
Which large funds own 4D Molecular Therapeutics, Inc.?
As of 2026Q2, among the large funds tracked: State Street, BlackRock, Goldman Sachs, Adage Capital Partners, Vanguard Group.